Synopsis
Synopsis
0
CEP/COS
0
EU WC
0
KDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Australia
0
South Africa
0
Listed Dossiers
Annual Reports
NA
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 2 Aminoethanethiol
2. 2-aminoethanethiol
3. 35s-labeled Cysteamine
4. Becaptan
5. Beta Mercaptoethylamine
6. Beta-mercaptoethylamine
7. Bitartrate, Cysteamine
8. Cystagon
9. Cysteamine
10. Cysteamine Dihydrochloride
11. Cysteamine Hydrobromide
12. Cysteamine Hydrochloride
13. Cysteamine Maleate (1:1)
14. Cysteamine Tartrate
15. Cysteamine Tartrate (1:1)
16. Cysteamine Tosylate
17. Cysteamine, 35s Labeled
18. Cysteamine, 35s-labeled
19. Cysteinamine
20. Dihydrochloride, Cysteamine
21. Hydrobromide, Cysteamine
22. Hydrochloride, Cysteamine
23. Mercamine
24. Mercaptamine
25. Mercaptoethylamine
26. Tartrate, Cysteamine
27. Tosylate, Cysteamine
1. 27761-19-9
2. Cysteamine (bitartrate)
3. Mercamine Bitartrate
4. Chebi:50386
5. Rp-103
6. Schembl49513
7. Chembl2062263
8. Bcp15048
9. Akos024332936
10. 2-aminoethanethiol 2,3-dihydroxysuccinate
11. Db-114321
12. Ft-0696891
13. 2-aminoethanethiol;2,3-dihydroxybutanedioic Acid
14. A900934
15. Q27122045
1. Cysteamine (usan)
2. Mecramine
Molecular Weight | 227.24 g/mol |
---|---|
Molecular Formula | C6H13NO6S |
Hydrogen Bond Donor Count | 6 |
Hydrogen Bond Acceptor Count | 8 |
Rotatable Bond Count | 4 |
Exact Mass | 227.04635831 g/mol |
Monoisotopic Mass | 227.04635831 g/mol |
Topological Polar Surface Area | 142 Ų |
Heavy Atom Count | 14 |
Formal Charge | 0 |
Complexity | 144 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 2 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
Cystine Depleting Agents
Compounds and drugs that react with CYSTINE and convert it into a compound that can be more easily metabolized or intracellularly transported. Drugs in this class have been used to treat CYSTINOSIS. (See all compounds classified as Cystine Depleting Agents.)
Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 37094
Submission : 2022-06-01
Status : Active
Type : II
Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.
Honour is a leading global CDMO and specialty chemicals manufacturer with seven world-class sites delivering quality-driven solutions.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 9619
Submission : 1992-09-30
Status : Active
Type : II
Registration Number : 225MF10146
Registrant's Address : Via Curiel 34, 20067 Paulo, Milano, ITALY
Initial Date of Registration : 2013-07-25
Latest Date of Registration :
NDC Package Code : 12828-0068
Start Marketing Date : 1993-02-22
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 27574
Submission : 2013-07-25
Status : Active
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2015-05-26
Pay. Date : 2013-09-06
DMF Number : 26816
Submission : 2013-09-05
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 35758
Submission : 2021-03-29
Status : Active
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2019-09-23
Pay. Date : 2019-09-12
DMF Number : 32668
Submission : 2018-04-13
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 38209
Submission : 2023-04-17
Status : Active
Type : II
Registration Number : 305MF10033
Registrant's Address : VIA M. Civitali, 1-20148 MILANO, ITALY
Initial Date of Registration : 2023-03-15
Latest Date of Registration :
Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 37094
Submission : 2022-06-01
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2015-05-26
Pay. Date : 2013-09-06
DMF Number : 26816
Submission : 2013-09-05
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 27574
Submission : 2013-07-25
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 9619
Submission : 1992-09-30
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2019-09-23
Pay. Date : 2019-09-12
DMF Number : 32668
Submission : 2018-04-13
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 35758
Submission : 2021-03-29
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 38209
Submission : 2023-04-17
Status : Active
Type : II
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 7405
Submission : 1988-03-26
Status : Inactive
Type : II
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Registration Number : 225MF10146
Registrant's Address : Via Curiel 34, 20067 Paulo, Milano, ITALY
Initial Date of Registration : 2013-07-25
Latest Date of Registration : 2023-02-15
Registration Number : 305MF10033
Registrant's Address : VIA M. Civitali, 1-20148 MILANO, ITALY
Initial Date of Registration : 2023-03-15
Latest Date of Registration : 2023-03-15
NDC Package Code : 17373-1199
Start Marketing Date : 2022-10-18
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 73377-300
Start Marketing Date : 2024-11-04
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT FOR HUMAN P...
NDC Package Code : 12828-0068
Start Marketing Date : 1993-02-22
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 71666-010
Start Marketing Date : 2020-04-24
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 46439-8762
Start Marketing Date : 2018-05-22
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
NDC Package Code : 82708-0007
Start Marketing Date : 1994-08-15
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
NDC Package Code : 69575-4054
Start Marketing Date : 2025-06-25
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (50kg/50kg)
Marketing Category : BULK INGREDIENT
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
About the Company : Biophore, founded in 2007, has established itself as a reliable partner in the development and manufacturing of niche and complex pharmaceutical products. With 4 USFDA and EU-appro...
Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
About the Company : Biophore, founded in 2007, has established itself as a reliable partner in the development and manufacturing of niche and complex pharmaceutical products. With 4 USFDA and EU-appro...
Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.
About the Company : Founded in 1987, Transo-Pharm is a fully licensed and certified global distributor of pharmaceutical components for the health and veterinary industries. The company supports its c...
About the Company : Alven Laboratories is a pharmaceutical company specializing in the development, scale-up, and production of original and generic Active Pharmaceutical Ingredients (APIs). With expe...
Honour is a leading global CDMO and specialty chemicals manufacturer with seven world-class sites delivering quality-driven solutions.
About the Company : Honour is a leading global CDMO and a trusted manufacturer of specialty chemicals and ingredients. With seven world-class facilities built to meet global safety and quality standar...
About the Company : Apicore LLC, a wholly owned subsidiary of RK Pharma Inc is a leading process R&D and API manufacturing service provider for the worldwide pharmaceutical industry. We offer a wide p...
About the Company : Lupin Manufacturing Solutions (LMS), a wholly owned Lupin subsidiary, offers high-quality APIs and end-to-end CDMO services from R&D to commercial scale. Backed by five decades of ...
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
Cyspera (cysteamine) is the clinically proven to provide effective treatment of hyperpigmentation without the concerns of corticosteroids, retinoic-acid and hydroquinoneused to treat hyperpigmentation.
Lead Product(s): Cysteamine Bitartrate
Therapeutic Area: Dermatology Brand Name: Cyspera
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 17, 2022
Lead Product(s) : Cysteamine Bitartrate
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Cyspera® Launches New Three-Step System with Novel Pigment Corrector to Treat Hyperpigmentation
Details : Cyspera (cysteamine) is the clinically proven to provide effective treatment of hyperpigmentation without the concerns of corticosteroids, retinoic-acid and hydroquinoneused to treat hyperpigmentation.
Product Name : Cyspera
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 17, 2022
Details:
Procysbi (cysteamine bitartrate) delayed-release capsules and delayed-release oral granules is a cystine-depleting agent indicated for the treatment of nephropathic cystinosis in adults and pediatric patients 1 year of age and older.
Lead Product(s): Cysteamine Bitartrate
Therapeutic Area: Genetic Disease Brand Name: Procysbi
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 27, 2020
Lead Product(s) : Cysteamine Bitartrate
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Horizon Therapeutics Plc Announces Availability of PROCYSBI® (Cysteamine Bitartrate) Delayed-Rele...
Details : Procysbi (cysteamine bitartrate) delayed-release capsules and delayed-release oral granules is a cystine-depleting agent indicated for the treatment of nephropathic cystinosis in adults and pediatric patients 1 year of age and older.
Product Name : Procysbi
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 27, 2020
Details:
Procysbi (cysteamine bitartrate) delayed-release capsules and delayed-release oral granules is a cystine-depleting agent indicated for the treatment of nephropathic cystinosis in adults and pediatric patients 1 year of age and older.
Lead Product(s): Cysteamine Bitartrate
Therapeutic Area: Genetic Disease Brand Name: Procysbi
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 18, 2020
Lead Product(s) : Cysteamine Bitartrate
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Horizon Therapeutics Plc Announces U.S. FDA Approval of New Dosage Form for PROCYSBI® (Cysteamine...
Details : Procysbi (cysteamine bitartrate) delayed-release capsules and delayed-release oral granules is a cystine-depleting agent indicated for the treatment of nephropathic cystinosis in adults and pediatric patients 1 year of age and older.
Product Name : Procysbi
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 18, 2020
Regulatory Info :
Registration Country : Canada
CYSTEAMINE (CYSTEAMINE BITARTRATE)
Brand Name : PROCYSBI
Dosage Form : CAPSULE (DELAYED RELEASE)
Dosage Strength : 25MG
Packaging : 50
Approval Date :
Application Number : 2464705
Regulatory Info :
Registration Country : Canada
Regulatory Info : RX
Registration Country : USA
Brand Name : PROCYSBI
Dosage Form : CAPSULE, DELAYED RELEASE;ORAL
Dosage Strength : EQ 25MG BASE
Packaging :
Approval Date : 2013-04-30
Application Number : 203389
Regulatory Info : RX
Registration Country : USA
Regulatory Info : RX
Registration Country : USA
Brand Name : PROCYSBI
Dosage Form : GRANULE, DELAYED RELEASE;ORAL
Dosage Strength : EQ 75MG BASE/PACKET
Packaging :
Approval Date : 2020-02-14
Application Number : 213491
Regulatory Info : RX
Registration Country : USA
Regulatory Info :
Registration Country : Sweden
Brand Name : CYSTAGON
Dosage Form : HARD CAPSULES
Dosage Strength : 50 MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Sweden
Brand Name : CYSTAGON
Dosage Form : HARD CAPSULES
Dosage Strength : 150 MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Italy
Brand Name : Cystagon
Dosage Form : Mercaptamine 150Mg 100 Unita' Oral Use
Dosage Strength : 100 cps 150 mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Norway
Brand Name : Cystagon
Dosage Form : Capsule, hard
Dosage Strength : 150 mg
Packaging : Box of plastic
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Norway
Brand Name : Cystagon
Dosage Form : Capsule, hard
Dosage Strength : 50 mg
Packaging : Box of plastic
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info : RX
Registration Country : USA
Brand Name : CYSTAGON
Dosage Form : CAPSULE;ORAL
Dosage Strength : EQ 150MG BASE
Packaging :
Approval Date : 1994-08-15
Application Number : 20392
Regulatory Info : RX
Registration Country : USA
Regulatory Info :
Registration Country : Sweden
Brand Name : Procysbi
Dosage Form : GASTRO-RESISTANT CAPSULE, HARD
Dosage Strength : 25 MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Sweden
Brand Name : CYSTAGON
Dosage Form : HARD CAPSULES
Dosage Strength : 50 MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Sweden
Brand Name : CYSTAGON
Dosage Form : HARD CAPSULES
Dosage Strength : 150 MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Italy
Brand Name : Cystagon
Dosage Form : Mercaptamine 50Mg 100 Unita' Oral Use
Dosage Strength : 100 cps 50 mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Italy
Brand Name : Cystagon
Dosage Form : Mercaptamine 150Mg 100 Unita' Oral Use
Dosage Strength : 100 cps 150 mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Norway
Brand Name : Cystagon
Dosage Form : Capsule, hard
Dosage Strength : 150 mg
Packaging : Box of plastic
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Norway
Brand Name : Cystagon
Dosage Form : Capsule, hard
Dosage Strength : 50 mg
Packaging : Box of plastic
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Sweden
Brand Name : Procysbi
Dosage Form : GASTRO-RESISTANT CAPSULE, HARD
Dosage Strength : 75 MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Sweden
Brand Name : Procysbi
Dosage Form : GASTRO-RESISTANT CAPSULE, HARD
Dosage Strength : 25 MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Norway
Brand Name : Procysbi
Dosage Form : Enteric Capsule
Dosage Strength : 25 mg
Packaging : Box
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Norway
Brand Name : Procysbi
Dosage Form : Enteric Capsule
Dosage Strength : 75 mg
Packaging : Box
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Dosage Form : Cream / Lotion / Ointment, Gel, Injectable / Parenteral, Softgels
Grade : Parenteral, Oral, Topical
Category : Film Formers & Plasticizers, Parenteral, Thickeners and Stabilizers, Topical
Dosage Form : Capsule, Cream / Lotion / Ointment
Grade : Topical and Oral
Category : Film Formers & Plasticizers, Topical
Application : Film Formers & Plasticizers, Topical
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
Patent Expiration Date : 2036-08-16
US Patent Number : 10143665
Drug Substance Claim :
Drug Product Claim :
Application Number : 203389
Patent Use Code : U-1399
Delist Requested :
Patent Use Description : MANAGEMENT OF NEPHROPA...
Patent Expiration Date : 2036-08-16
Patent Expiration Date : 2027-01-26
US Patent Number : 9925156
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 203389
Patent Use Code : U-1399
Delist Requested :
Patent Use Description : MANAGEMENT OF NEPHROPA...
Patent Expiration Date : 2027-01-26
Patent Expiration Date : 2034-12-17
US Patent Number : 9173851*PED
Drug Substance Claim :
Drug Product Claim :
Application Number : 203389
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2034-12-17
Patent Expiration Date : 2027-07-26
US Patent Number : 9925157*PED
Drug Substance Claim :
Drug Product Claim :
Application Number : 213491
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2027-07-26
Patent Expiration Date : 2027-07-26
US Patent Number : 9192590*PED
Drug Substance Claim :
Drug Product Claim :
Application Number : 203389
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2027-07-26
Patent Expiration Date : 2027-01-26
US Patent Number : 9925157
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 213491
Patent Use Code : U-1399
Delist Requested :
Patent Use Description : MANAGEMENT OF NEPHROPA...
Patent Expiration Date : 2027-01-26
Patent Expiration Date : 2027-07-26
US Patent Number : 9192590*PED
Drug Substance Claim :
Drug Product Claim :
Application Number : 213491
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2027-07-26
Patent Expiration Date : 2027-07-26
US Patent Number : 9198882*PED
Drug Substance Claim :
Drug Product Claim :
Application Number : 213491
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2027-07-26
Exclusivity Code : ODE-162
Exclusivity Expiration Date : 2024-12-22
Application Number : 203389
Product Number : 1
Exclusivity Details :
Exclusivity Code : ODE-162
Exclusivity Expiration Date : 2024-12-22
Application Number : 203389
Product Number : 2
Exclusivity Details :
Exclusivity Code : ODE*
Exclusivity Expiration Date : 2024-12-22
Application Number : 213491
Product Number : 1
Exclusivity Details :
Exclusivity Code : ODE*
Exclusivity Expiration Date : 2024-12-22
Application Number : 213491
Product Number : 2
Exclusivity Details :
Exclusivity Code : PED
Exclusivity Expiration Date : 2025-06-22
Application Number : 203389
Product Number : 1
Exclusivity Details :
Exclusivity Code : PED
Exclusivity Expiration Date : 2025-06-22
Application Number : 203389
Product Number : 2
Exclusivity Details :
Exclusivity Code : PED
Exclusivity Expiration Date : 2025-06-22
Application Number : 213491
Product Number : 1
Exclusivity Details :
Exclusivity Code : PED
Exclusivity Expiration Date : 2025-06-22
Application Number : 213491
Product Number : 2
Exclusivity Details :
ABOUT THIS PAGE
13
PharmaCompass offers a list of Cysteamine Bitartrate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Cysteamine Bitartrate manufacturer or Cysteamine Bitartrate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Cysteamine Bitartrate manufacturer or Cysteamine Bitartrate supplier.
PharmaCompass also assists you with knowing the Cysteamine Bitartrate API Price utilized in the formulation of products. Cysteamine Bitartrate API Price is not always fixed or binding as the Cysteamine Bitartrate Price is obtained through a variety of data sources. The Cysteamine Bitartrate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A PROCYSBI manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of PROCYSBI, including repackagers and relabelers. The FDA regulates PROCYSBI manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. PROCYSBI API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of PROCYSBI manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A PROCYSBI supplier is an individual or a company that provides PROCYSBI active pharmaceutical ingredient (API) or PROCYSBI finished formulations upon request. The PROCYSBI suppliers may include PROCYSBI API manufacturers, exporters, distributors and traders.
click here to find a list of PROCYSBI suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A PROCYSBI DMF (Drug Master File) is a document detailing the whole manufacturing process of PROCYSBI active pharmaceutical ingredient (API) in detail. Different forms of PROCYSBI DMFs exist exist since differing nations have different regulations, such as PROCYSBI USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A PROCYSBI DMF submitted to regulatory agencies in the US is known as a USDMF. PROCYSBI USDMF includes data on PROCYSBI's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The PROCYSBI USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of PROCYSBI suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The PROCYSBI Drug Master File in Japan (PROCYSBI JDMF) empowers PROCYSBI API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the PROCYSBI JDMF during the approval evaluation for pharmaceutical products. At the time of PROCYSBI JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of PROCYSBI suppliers with JDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing PROCYSBI as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for PROCYSBI API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture PROCYSBI as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain PROCYSBI and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a PROCYSBI NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of PROCYSBI suppliers with NDC on PharmaCompass.
PROCYSBI Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of PROCYSBI GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right PROCYSBI GMP manufacturer or PROCYSBI GMP API supplier for your needs.
A PROCYSBI CoA (Certificate of Analysis) is a formal document that attests to PROCYSBI's compliance with PROCYSBI specifications and serves as a tool for batch-level quality control.
PROCYSBI CoA mostly includes findings from lab analyses of a specific batch. For each PROCYSBI CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
PROCYSBI may be tested according to a variety of international standards, such as European Pharmacopoeia (PROCYSBI EP), PROCYSBI JP (Japanese Pharmacopeia) and the US Pharmacopoeia (PROCYSBI USP).